<DOC>
	<DOCNO>NCT02223897</DOCNO>
	<brief_summary>Ischemic-type biliary lesion ( ITBLs ) major cause graft loss mortality orthotopic liver transplantation ( OLT ) . For , still lack effective treatment ITBLs . The purpose study confirm whether human umbilical cord mesenchymal stem cell effective treatment , prevention Ischemic-type Biliary Lesions liver transplantation .</brief_summary>
	<brief_title>Mesenchymal Stem Cells Transplantation Ischemic-type Biliary Lesions</brief_title>
	<detailed_description>Advances organ preservation technique , immunosuppressive regimen , surgical technique result reduced rate infection , acute rejection vascular complication orthotopic liver transplantation ( OLT ) . However , ischemic-type biliary lesion ( ITBLs ) still one serious complication OLT , usual report incidence 5-15 % , incidence 26 % study . 46 % patient ITBLs require re-transplantation 2 year OLT . Mesenchymal stem cell ( MSCs ) , kind pluripotent stem cell , differentiate vascular endothelial cell , participate angiogenesis ischemic tissue . MSCs also stimulate proliferation migration mature endothelial cell via paracrine.Furthermore , MSCs secret variety cytokine growth factor , vascular endothelial growth factor , human basic fibroblast growth factor , hepatocyte growth factor , interleukin-1 interleukin-8 , etc. , also induce angiogenesis . Participants study randomly assign one two treatment arm : - Arm A : Participants receive 6 month standard regular treatment ITBLs plus huc-MSCs treatment . - Arm B : Participants receive 6 month standard regular treatment ITBLs plus placebo . huc-MSCs prepared accord standard procedure collect plastic bag contain anti coagulant . MSCs give via i.v . After huc-MSCs transfusion , patient follow per week ( first month , &lt; 1M ) , per 2 week ( 1-3M ) per month ( 3-6M ) , evaluation liver function biliary blood supply perform .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<criteria>benign endstage liver disease patient liver transplantation . age 18 60 year . first liver transplant . gammaglutamyltransferase &gt; 300 U/L 2 week , low enhancement wall hilar bile duct arterial phase via contrastenhanced ultrasonography . Written informed consent . second combined organ transplant recipient . vital organ failure ( Cardiac , Renal Respiratory , et al ) . clinically active bacterial , fungal , viral parasitic infection . candidate judge applicable study investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Liver transplantation</keyword>
	<keyword>Biliary complication</keyword>
	<keyword>mesenchymal stem cell</keyword>
</DOC>